IMUNON’s IL‑12 DNA immunotherapy IMNN‑001 advances in pivotal Phase 3 OVATION 3 ovarian cancer trial after iDMC endorsement, building on Phase 2 survival gains and positioning for potential accelerated FDA review.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
IMUNON has received a positive recommendation from the independent Data Monitoring Committee (iDMC) to continue its pivotal Phase 3 OVATION 3 trial (NCT06915025) evaluating IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy for women with newly diagnosed advanced ovarian cancer. The committee found no safety concerns requiring protocol changes, allowing the study to proceed as planned.
The company also reported that patient recruitment remains ahead of schedule, with 27 participants enrolled and approximately 80 patients expected to be enrolled by the end of the first quarter of 2027. OVATION 3 is the registrational study intended to support potential regulatory approval of IMNN-001, an investigational DNA-mediated immunotherapy.
Novel IL-12 Immunotherapy Targets Ovarian Cancer Microenvironment
IMNN-001 is based on IMUNON’s proprietary TheraPlas® platform and consists of an IL-12 DNA plasmid delivered through a nanoparticle system directly into the peritoneal cavity. The approach enables localized production of interleukin-12, a cytokine known to stimulate T-cell and natural killer cell activity against cancer.
Advanced epithelial ovarian cancer remains one of the deadliest gynecologic malignancies. Nearly 70% of patients are diagnosed at stage III or IV disease, and recurrence rates remain high despite surgery and platinum-based chemotherapy. Five-year survival remains poor, creating a significant need for therapies that can extend survival beyond current standards of care.
Phase 3 Study Builds on Encouraging Survival Gains
OVATION 3 will enroll approximately 500 patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants are randomized to receive either standard neoadjuvant and adjuvant chemotherapy with paclitaxel and carboplatin or the same regimen plus IMNN-001.
The study’s primary endpoint is overall survival, with additional measures including objective response rate, chemotherapy response score, surgical response score, and time to second-line therapy. Two planned interim analyses could potentially support an earlier biologics license application (BLA) submission if survival benefits reach statistical significance.
The trial follows results from the Phase 2 OVATION 2 study (NCT03393884), which enrolled 112 patients. Although not powered for statistical significance, the study reported a median overall survival of 45.1 months for patients receiving IMNN-001 plus chemotherapy compared with 30.4 months for standard treatment alone, representing a 14.7-month improvement.
Among patients who subsequently received PARP inhibitor maintenance therapy, median overall survival reached 65.6 months in the IMNN-001 group versus 41.4 months in the control arm, a difference of 24.2 months. IMNN-001 also maintained a favorable safety and tolerability profile throughout the study.
Leadership Highlights Continued Momentum
Chief Executive Officer Stacy Lindborg, Ph.D., said the iDMC recommendation provides additional validation of the efficacy and safety findings generated across previous clinical studies. She noted that enrollment progress remains ahead of expectations and emphasized the company’s commitment to advancing the trial as rapidly as possible.
Regulatory Path Forward
IMUNON plans to continue expanding enrollment across U.S. clinical sites while advancing toward the study’s interim analyses. If the survival endpoint demonstrates statistically significant benefit during these planned reviews, the company could pursue an accelerated regulatory pathway for IMNN-001. Success in OVATION 3 would position the therapy as a potential new treatment option for women facing advanced ovarian cancer, a disease where meaningful improvements in overall survival remain difficult to achieve.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.